Drug Profile
Research programme: inflammation therapy - Ogeda/Merck & Co
Alternative Names: ESN 282Latest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator Euroscreen
- Developer Merck & Co; Ogeda
- Class Anti-inflammatories; Small molecules
- Mechanism of Action G-protein coupled receptor 43 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for preclinical development in Inflammation in Belgium
- 28 Oct 2020 No recent reports of development identified for preclinical development in Inflammation in USA
- 16 May 2017 Ogeda has been acquired by and became a wholly-owned subsidiary of Astellas Pharma